Bio-Path (BPTH) Competitors $0.16 -0.01 (-3.62%) As of 12:55 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock BPTH vs. ATNF, CYCC, ENSC, GLTO, KTTA, ALBT, APM, MTNB, VIVS, and RDHLShould you be buying Bio-Path stock or one of its competitors? The main competitors of Bio-Path include 180 Life Sciences (ATNF), Cyclacel Pharmaceuticals (CYCC), Ensysce Biosciences (ENSC), Galecto (GLTO), Pasithea Therapeutics (KTTA), Avalon GloboCare (ALBT), Aptorum Group (APM), Matinas Biopharma (MTNB), VivoSim Labs (VIVS), and Redhill Biopharma (RDHL). These companies are all part of the "pharmaceutical products" industry. Bio-Path vs. Its Competitors 180 Life Sciences Cyclacel Pharmaceuticals Ensysce Biosciences Galecto Pasithea Therapeutics Avalon GloboCare Aptorum Group Matinas Biopharma VivoSim Labs Redhill Biopharma 180 Life Sciences (NASDAQ:ATNF) and Bio-Path (NASDAQ:BPTH) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, earnings, dividends, media sentiment, valuation, risk and institutional ownership. Does the media favor ATNF or BPTH? In the previous week, 180 Life Sciences had 3 more articles in the media than Bio-Path. MarketBeat recorded 3 mentions for 180 Life Sciences and 0 mentions for Bio-Path. 180 Life Sciences' average media sentiment score of 0.63 beat Bio-Path's score of 0.00 indicating that 180 Life Sciences is being referred to more favorably in the media. Company Overall Sentiment 180 Life Sciences Positive Bio-Path Neutral Which has higher earnings and valuation, ATNF or BPTH? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio180 Life SciencesN/AN/A-$6.17M-$14.76-0.06Bio-PathN/AN/A-$16.08MN/AN/A Which has more volatility & risk, ATNF or BPTH? 180 Life Sciences has a beta of 0.22, indicating that its stock price is 78% less volatile than the S&P 500. Comparatively, Bio-Path has a beta of -0.03, indicating that its stock price is 103% less volatile than the S&P 500. Is ATNF or BPTH more profitable? 180 Life Sciences' return on equity of -147.34% beat Bio-Path's return on equity.Company Net Margins Return on Equity Return on Assets 180 Life SciencesN/A -147.34% -77.00% Bio-Path N/A -2,842.40%-337.48% Do institutionals and insiders believe in ATNF or BPTH? 4.1% of 180 Life Sciences shares are owned by institutional investors. Comparatively, 5.7% of Bio-Path shares are owned by institutional investors. 38.2% of 180 Life Sciences shares are owned by insiders. Comparatively, 0.7% of Bio-Path shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Summary180 Life Sciences beats Bio-Path on 7 of the 8 factors compared between the two stocks. Get Bio-Path News Delivered to You Automatically Sign up to receive the latest news and ratings for BPTH and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BPTH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BPTH vs. The Competition Export to ExcelMetricBio-PathPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.30M$752.09M$5.52B$9.32BDividend YieldN/A4.84%4.25%4.05%P/E RatioN/A1.4328.1519.68Price / SalesN/A25.51437.63100.28Price / CashN/A19.5635.5357.53Price / Book0.226.608.235.67Net Income-$16.08M-$4.53M$3.23B$257.51M7 Day Performance-4.91%1.40%-0.01%0.52%1 Month Performance-17.37%1.30%5.61%8.84%1 Year Performance-91.82%3.42%26.52%14.18% Bio-Path Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BPTHBio-Path0.8215 of 5 stars$0.16-3.6%N/A-91.5%$1.30MN/A0.0010ATNF180 Life Sciences0.7793 of 5 stars$0.90-0.7%N/A-56.0%$5.44MN/A-0.067News CoverageCYCCCyclacel Pharmaceuticals1.2348 of 5 stars$3.31-10.8%N/A-97.0%$5.25M$14K0.0014Trending NewsGap DownHigh Trading VolumeENSCEnsysce Biosciences0.6137 of 5 stars$2.20+1.9%N/A-69.5%$5.22MN/A-0.3410News CoverageGLTOGalecto3.2229 of 5 stars$3.90+10.2%$10.00+156.4%-76.0%$5.15MN/A-0.2540KTTAPasithea Therapeutics1.6125 of 5 stars$0.69+0.1%N/A-88.7%$5.14MN/A-0.073ALBTAvalon GloboCare1.3342 of 5 stars$2.71+6.3%N/A-63.0%$5.13M$1.37M-0.145News CoverageGap UpHigh Trading VolumeAPMAptorum Group2.0649 of 5 stars$0.95+1.2%N/A-77.5%$5.10M$430K0.0030News CoveragePositive NewsTrading HaltedMTNBMatinas BiopharmaN/A$1.00-2.9%N/AN/A$5.09MN/A-0.2130VIVSVivoSim LabsN/A$1.94+0.0%N/AN/A$5.04M$140K-0.1920Positive NewsRDHLRedhill BiopharmaN/A$2.18-0.5%N/A-99.2%$5.00M$8.04M0.00210Positive News Related Companies and Tools Related Companies ATNF Alternatives CYCC Alternatives ENSC Alternatives GLTO Alternatives KTTA Alternatives ALBT Alternatives APM Alternatives MTNB Alternatives VIVS Alternatives RDHL Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BPTH) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | Sponsored"Death Spiral" Threatening Your SavingsThe "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…GoldCo Precious Metals | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored[ATTENTION] This Crypto Rocket Is About Launch…Every crypto bull market ends with a final surge — the window where fortunes are made fast. According to tw...Crypto Swap Profits | SponsoredIs this secretive Asian company trying to take over Bitcoin?A mysterious Asian conglomerate is buying billions in Bitcoin — but one legendary trader says that’s the wrong...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bio-Path Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bio-Path With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BPTH Stock Alerts